On the stock market since 2018, it operates in the world of health and science. It has 258 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Buys outnumber sells, but taken together the trades don’t add up to a strong signal of confidence.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
There is growth, but not at top-of-the-class tempo.
The stock has been running stronger than the market lately.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
There is $900.8M in the vault; even if every debt were paid off, $647.6M would remain.
The average analyst price target is $46.75 — 20% above today’s price.
A loss of $328.9M against $0 in annual sales.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 41/100.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
On our five-subject report card, COGT sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: COGT is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (51/100) says the stock isn’t cheap.